Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans

Clinical Pharmacology and Therapeutics
K Hartigan-GoS H Thomas

Abstract

To measure cardiac and other effects of thioridazine and relate these to the plasma concentration of the parent drug and its principal metabolites. A double-blind, randomized-order crossover study involving nine healthy male subjects compared the effects of single doses of thioridazine (10 mg and 50 mg) with placebo. Plasma concentrations of thioridazine and its ring sulfoxide, side-chain sulfoxide, and side-chain sulfone metabolites were measured, together with effects on the ECG, blood pressure, salivary flow, and a batch of psychomotor tests for 72 hours after administration. Thioridazine, 50 mg, reduced standing systolic blood pressure (mean peak changes from baseline [95% CI] -32 mm Hg [-55, 10 mm Hg]; p < 0.01 versus placebo) and diastolic blood pressure (-14 mm Hg [-26, -2 mm Hg]; p < 0.05), increased standing heart rate (7 beats/min [-1, 16 beats/min]; p < 0.05), impaired psychomotor function, and prolonged the JT (20 ms1/2 [7, 34 ms1/2]; p < 0.05), QTa (22 ms1/2 [8, 36 ms1/2]; p < 0.05), and QTc (22 ms1/2 [11, 33 ms1/2]; p < 0.01) intervals, but had no effect on QT dispersion (-12 ms1/2 [-31, 6 ms1/2]). Thioridazine, 1.0 mg, also significantly increased QTc, but the effect was less marked (9 ms1/2 [-1, 19 ms1/2]; p < 0...Continue Reading

References

Feb 1, 1976·The American Journal of Cardiology·N O FowlerI B Hanenson
Dec 18, 1978·European Journal of Clinical Pharmacology·G NybergE Mårtensson
Jan 1, 1979·British Journal of Clinical Pharmacology·I Hindmarch
Jun 1, 1979·The American Journal of Cardiology·M S YoonS A Jones
Jan 1, 1976·Clinical Pharmacology and Therapeutics·C T DolleryS Murray
May 1, 1991·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S C Newman, R C Bland
Mar 1, 1991·Clinical Pharmacology and Therapeutics·C von BahrF Sjöqvist
Jan 1, 1987·Biological Psychiatry·N KiriikeT Takeda
Jul 8, 1968·JAMA : the Journal of the American Medical Association·T D Giles, R K Modlin
Nov 1, 1966·Annals of Internal Medicine·F W SchoonmakerJ C Greenfield
Jun 3, 1983·JAMA : the Journal of the American Medical Association·A J KemperD A Pietro
Jun 1, 1980·The British Journal of Psychiatry : the Journal of Mental Science·A S PapadopoulosS Lader
Jul 1, 1996·Clinical Pharmacology and Therapeutics·K Hartigan-GoS H Thomas
Jan 1, 1996·Methods in Enzymology·A K DalyJ R Idle
Jun 21, 1965·JAMA : the Journal of the American Medical Association·L E HOLLISTER, J C KOSEK

❮ Previous
Next ❯

Citations

Sep 5, 2002·British Journal of Clinical Pharmacology·Rashmi R Shah
Aug 10, 2002·The Australian and New Zealand Journal of Psychiatry·David B Menkes, James C Knight
May 11, 2007·Journal of Child and Adolescent Psychopharmacology·Eitan NahshoniAbraham Weizman
Aug 13, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Rashmi R Shah
Feb 4, 2003·Journal of Child and Adolescent Psychiatric Nursing : Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc·Deirdre H CarrollLawrence Scahill
Jan 1, 2009·Pediatric Reports·Zenichiro KatoNaomi Kondo
Mar 22, 2001·British Journal of Clinical Pharmacology·S J de VisserJ M van Gerven
Jan 19, 2016·Journal of Child and Adolescent Psychopharmacology·José A AldaCelso Arango
Jul 30, 2003·Pharmacotherapy·Michael A CrouchAngela T Cassano
Sep 4, 2007·British Journal of Clinical Pharmacology·H K R Thanacoody
Oct 20, 2005·Pharmacotherapy·Mori J KrantzJulia H Arnsten
Feb 3, 2007·Expert Opinion on Drug Metabolism & Toxicology·Pedro DoradoAdrián Llerena
Oct 22, 2011·Expert Opinion on Investigational Drugs·Sadhna Sharma, Amandeep Singh
May 9, 2002·Expert Opinion on Pharmacotherapy·Paul J GoodnickFrancisco Parra
Jun 6, 2008·Journal of Clinical Pharmacology·J Andrew WilliamsSteven A Wrighton
Jan 8, 2004·Journal of Clinical Psychopharmacology·Edmund P HarriganMichelle Middle
Sep 17, 2004·European Journal of Clinical Pharmacology·E M StrachanD N Bateman
Dec 17, 2014·Journal of Clinical Pharmacology·Alexandre ChigaevStuart S Winter
Jun 27, 2003·Journal of Clinical Psychopharmacology·Nancy C BrahmRobert D Brown
Apr 27, 2007·Clinical Pharmacology and Therapeutics·R H K ThanacoodyS H L Thomas
Nov 26, 2009·Journal of Psychiatric Practice·Sheldon H Preskorn
Aug 13, 2005·International Clinical Psychopharmacology·Claudia StöllbergerJosef Finsterer
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N A Buckley, P Sanders
Feb 6, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R Shah
Jan 13, 2004·Clinical Pharmacokinetics·Candace S BrownSamantha F Eichner
Jul 27, 2000·The British Journal of Psychiatry : the Journal of Mental Science·L ApplebyT Amos
Dec 31, 2002·Adverse Drug Reactions and Toxicological Reviews·Barbara Warner, Peter Hoffmann
Dec 10, 1999·Journal of Clinical Psychopharmacology·J A CarrilloJ Benítez
May 18, 2012·British Journal of Clinical Pharmacology·Rashmi R Shah, Devron R Shah
Jan 22, 2003·Acta Psychiatrica Scandinavica·D M Taylor
Jun 20, 2003·British Journal of Clinical Pharmacology·D N BatemanC A Kelly
Mar 16, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·O D OstroumovaA P Pereverzev
Jun 22, 2019·Therapeutic Advances in Drug Safety·Onanong WaleekhachonloetThananan Rattanachotphanit
Apr 22, 2020·Antimicrobial Agents and Chemotherapy·Mike Marvin RuthJakko van Ingen
Jun 9, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Shogo J Miyagi, Abby C Collier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Psychiatry in Clinical Practice
M W Agelink Thomas Zeit Bruno Baumann Thomas Majewski Wimar Lemmer Thomas Postert Katrin Lukas Eckhard Klieser
© 2021 Meta ULC. All rights reserved